GlassScriptPhysician profile
Veronica Epstein
NPI 1962465195
$4,796.59
in general payments reported to CMS, 2019-2025
23 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $52.57 · 2021: $16.13 · 2022: $355 · 2023: $870 · 2024: $1,912 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,247.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,220.83 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $973.04 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $678.50 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $458.34 | 2021-2025 | |
| Lilly USA, LLC | $373.91 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $149.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $145.12 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $123.43 | 2025 | |
| Astellas Pharma US INC | $115.57 | 2024-2025 | Veozah |
| Shield Therapeutics INC | $88.81 | 2024 | |
| Dexcom, INC. | $87.13 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $68.89 | 2025 | Krystexxa, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.32 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Ucb, INC. | $48.13 | 2024-2025 | Nayzilam |
| Hikma Pharmaceuticals USA | $35.02 | 2023-2024 | Ryaltris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $34.03 | 2023-2024 | Korlym |
| Alnylam Pharmaceuticals INC. | $33.70 | 2024 | Givlaari |
| Aerin Medical INC. | $25.37 | 2025 | |
| Sumitomo Pharma America, INC. | $21.16 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.54 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $17.33 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $14.15 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $13.35 | 2023 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.